I feel you. What's worse: amyloid aggregates aren't fraud either, but certain ones are more conducive to fraud, and the fraudsters have been loudly denounced.
There is absolutely no question--none at all--that amyloid plaques are a key feature of Alzheimer disease, that they are neurotoxic, and that they fit within a number of mechanistic pathways contributing to dementia (which is the broad clinical phenotype).
Interestingly enough, the actual results of the lecanemab (Leqembi) trial is that those on drug had overall 17 months longer in the mild cognitive impairment / mild dementia range before declining to the moderate dementia range. It doesn't stop the disease, but it does measurably slow its course, and that makes a huge difference to families. Whether the linked author can accept that progress is mostly incremental and not wholly satisfying is, I don't know...his problem, but it is rapidly becoming our problem as dementia scientists.
There is absolutely no question--none at all--that amyloid plaques are a key feature of Alzheimer disease, that they are neurotoxic, and that they fit within a number of mechanistic pathways contributing to dementia (which is the broad clinical phenotype).
Interestingly enough, the actual results of the lecanemab (Leqembi) trial is that those on drug had overall 17 months longer in the mild cognitive impairment / mild dementia range before declining to the moderate dementia range. It doesn't stop the disease, but it does measurably slow its course, and that makes a huge difference to families. Whether the linked author can accept that progress is mostly incremental and not wholly satisfying is, I don't know...his problem, but it is rapidly becoming our problem as dementia scientists.
But people love a conspiracy.